company background image
NXS

Next Science ASX:NXS Stock Report

Last Price

AU$0.94

Market Cap

AU$208.3m

7D

-3.1%

1Y

-38.2%

Updated

11 Aug, 2022

Data

Company Financials +
NXS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

NXS Stock Overview

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.

Next Science Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share PriceAU$0.94
52 Week HighAU$1.55
52 Week LowAU$0.70
Beta0.81
1 Month Change13.25%
3 Month Change5.62%
1 Year Change-38.16%
3 Year Change-63.71%
5 Year Changen/a
Change since IPO-30.37%

Recent News & Updates

Shareholder Returns

NXSAU Medical EquipmentAU Market
7D-3.1%-0.2%0.5%
1Y-38.2%-18.3%-8.8%

Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -17.5% over the past year.

Return vs Market: NXS underperformed the Australian Market which returned -8.1% over the past year.

Price Volatility

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Average Weekly Movement11.6%
Medical Equipment Industry Average Movement11.5%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.8%
10% least volatile stocks in AU Market4.6%

Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NXS's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aJudy Mitchellhttps://www.nextscience.com

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.

Next Science Limited Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXS fundamental statistics
Market CapUS$147.81m
Earnings (TTM)-US$9.35m
Revenue (TTM)US$8.95m

16.0x

P/S Ratio

-15.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXS income statement (TTM)
RevenueUS$8.95m
Cost of RevenueUS$2.01m
Gross ProfitUS$6.94m
Other ExpensesUS$16.29m
Earnings-US$9.35m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.044
Gross Margin77.56%
Net Profit Margin-104.49%
Debt/Equity Ratio0%

How did NXS perform over the long term?

See historical performance and comparison